Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACON NASDAQ:FRES NYSE:LH NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.31-0.2%$7.13$6.20▼$3,499.51$4.24M1.3458,424 shs10,142 shsFRESFresh2 Group$0.85$0.96$0.73▼$3.40$765K1.332,195 shsN/ALHLabcorp$252.25-2.6%$253.38$198.96▼$265.72$21.13B0.82642,448 shs657,598 shsNTRANatera$162.80+0.6%$160.74$92.14▼$183.00$22.21B1.731.42 million shs486,688 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion-3.81%-2.59%+2.66%-14.69%-99.73%FRESFresh2 Group0.00%0.00%0.00%0.00%-72.68%LHLabcorp+0.69%-0.22%+1.45%+18.54%+30.15%NTRANatera+2.06%+0.11%-1.49%+12.89%+47.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion2.2337 of 5 stars3.03.00.00.02.30.01.3FRESFresh2 GroupN/AN/AN/AN/AN/AN/AN/AN/ALHLabcorp4.454 of 5 stars2.42.02.54.23.52.51.3NTRANatera2.1423 of 5 stars2.52.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.00Hold$11,758.50160,865.09% UpsideFRESFresh2 Group 4.00Strong BuyN/AN/ALHLabcorp 2.71Moderate Buy$276.389.57% UpsideNTRANatera 3.00Buy$184.6313.41% UpsideCurrent Analyst Ratings BreakdownLatest FRES, ACON, NTRA, and LH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025LHLabcorpHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$260.007/9/2025LHLabcorpEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $285.006/25/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingCautious ➝ Cautious6/25/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $275.006/11/2025LHLabcorpMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$270.00 ➝ $283.005/30/2025ACONAclarionAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/12/2025LHLabcorpTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$274.00 ➝ $290.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/6/2025LHLabcorpPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$260.00 ➝ $280.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$50K84.74N/AN/A$51.50 per share0.14FRESFresh2 Group$1.75M0.44N/AN/AN/A∞LHLabcorp$13.01B1.62$21.95 per share11.49$96.27 per share2.62NTRANatera$1.70B13.10N/AN/A$9.05 per share17.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$6.99MN/A0.00N/AN/A-12,227.10%-126.89%-106.61%8/13/2025 (Estimated)FRESFresh2 Group-$14.77MN/A0.00∞N/AN/AN/AN/AN/ALHLabcorp$746M$8.6529.1914.381.635.55%15.27%6.97%7/24/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)Latest FRES, ACON, NTRA, and LH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025LHLabcorp$4.12N/AN/AN/A$3.49 billionN/A5/15/2025Q1 2025ACONAclarion-$1,447.20-$9.32+$1,437.88-$9.32$0.02 million$0.02 million5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/29/2025Q1 2025LHLabcorp$3.73$3.84+$0.11$2.52$3.41 billion$3.35 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/AFRESFresh2 GroupN/AN/AN/AN/AN/ALHLabcorp$2.881.14%N/A33.29%N/ANTRANateraN/AN/AN/AN/AN/ALatest FRES, ACON, NTRA, and LH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/10/2025LHLabcorpquarterly$0.721.11%8/28/20259/11/20254/10/2025LHLabcorpquarterly$0.721.25%5/29/20256/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A21.6821.68FRESFresh2 GroupN/AN/AN/ALHLabcorp0.681.841.60NTRANateraN/A3.873.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%FRESFresh2 Group0.45%LHLabcorp95.94%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%FRESFresh2 Group26.22%LHLabcorp0.84%NTRANatera7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7580,000578,000Not OptionableFRESFresh2 Group75900,000663,000Not OptionableLHLabcorp70,00083.70 million83.00 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableFRES, ACON, NTRA, and LH HeadlinesRecent News About These CompaniesTeacher Retirement System of Texas Decreases Stake in Natera, Inc. (NASDAQ:NTRA)July 10 at 3:50 AM | marketbeat.comBank of New York Mellon Corp Has $132.45 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)July 9 at 5:15 AM | marketbeat.comLee Johnson Capital Management LLC Invests $3.68 Million in Natera, Inc. (NASDAQ:NTRA)July 8 at 7:38 AM | marketbeat.com226,000 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Ninety One UK LtdJuly 8 at 7:07 AM | marketbeat.comNatera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal CancerJuly 7 at 10:07 AM | finance.yahoo.comNatera, Inc. (NASDAQ:NTRA) Stock Holdings Increased by Calamos Advisors LLCJuly 6, 2025 | marketbeat.comPrincipal Financial Group Inc. Sells 91,190 Shares of Natera, Inc. (NASDAQ:NTRA)July 5, 2025 | marketbeat.comSumitomo Mitsui DS Asset Management Company Ltd Makes New Investment in Natera, Inc. (NASDAQ:NTRA)July 5, 2025 | marketbeat.comShould You Invest in Natera (NTRA)?July 4, 2025 | msn.comNatera, Inc. (NASDAQ:NTRA) Insider Sells $500,310.00 in StockJuly 4, 2025 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Shares Sold by KBC Group NVJuly 4, 2025 | marketbeat.comSolomon Moshkevich Sells 3,000 Shares of Natera, Inc. (NASDAQ:NTRA) StockJuly 3, 2025 | marketbeat.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,299 Shares of StockJuly 3, 2025 | marketbeat.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 5,343 Shares of StockJuly 3, 2025 | marketbeat.com1 Growth Stock with Exciting Potential and 2 to Be Wary OfJuly 3, 2025 | msn.comRobeco Institutional Asset Management B.V. Purchases Shares of 11,600 Natera, Inc. (NASDAQ:NTRA)July 2, 2025 | marketbeat.comNatera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRDJuly 1, 2025 | businesswire.comMirae Asset Global Investments Co. Ltd. Has $8.07 Million Position in Natera, Inc. (NASDAQ:NTRA)July 1, 2025 | marketbeat.comQ1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)June 30, 2025 | msn.comK.J. Harrison & Partners Inc Acquires 4,000 Shares of Natera, Inc. (NASDAQ:NTRA)June 29, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Boosts Holdings in Natera, Inc. (NASDAQ:NTRA)June 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendRocket Lab: Latest Catalysts Bolster the Bull CaseBy Ryan Hasson | July 3, 2025View Rocket Lab: Latest Catalysts Bolster the Bull CaseMicron Insiders Sell But Investors Should Buy, Buy, BuyBy Thomas Hughes | July 7, 2025View Micron Insiders Sell But Investors Should Buy, Buy, BuyMicron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingBy Thomas Hughes | June 26, 2025View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingNike Stock: The Mother of All Comebacks Might Have Just BegunBy Sam Quirke | June 27, 2025View Nike Stock: The Mother of All Comebacks Might Have Just BegunFRES, ACON, NTRA, and LH Company DescriptionsAclarion NASDAQ:ACON$7.30 -0.02 (-0.20%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Fresh2 Group NASDAQ:FRESFresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.Labcorp NYSE:LH$252.25 -6.82 (-2.63%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$162.80 +1.05 (+0.65%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Boeing's Rebound Is Well Underway—But Is It Too Late? Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
